4th Quarter - Report

ALLIANCE FOR AGING RESEARCH for ALLIANCE FOR AGING RESEARCH

Firm
Client
Income
—
Expenses
—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

-FDA Prescription Drug User Fee Reauthorization -Dr. Robert Califf FDA Commissioner Nomination -Antimicrobial Resistance appropriations request for CDC, ASPR, NIH, FDA, and USDA programs

LobbyistCovered position, as disclosed
RYNE C. CARNEY Intern Rep. Ed Perlmutter
MICHAEL WARD New —

Contacted: Centers For Medicare and Medicaid Services (CMS); White House Office; HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

-Held meetings and submitted letters on prescription drug pricing reform recommendations including measures to enhance affordability, limiting out-of-pocket expenses for beneficiaries, moderating annual increases in drug prices, restructuring the cost-sharing, expanding Medicare services to include dental, hearing, and vision, and recommended a federal ban on the quality-adjusted life year. -Step Therapy in Medicare Advantage -National Family and Medical Paid Leave Program -Section 139402 (provide first-dollar coverage of adult vaccines recommended by the Advisory Committee on Immunization Practices under Medicare Part D;) and Section 139405 ( improve access to adult vaccines under Medicaid and CHIP by providing a federal baseline for first-dollar coverage and an enhanced FMAP for immunizing providers.) of the Build Back Better Act.

LobbyistCovered position, as disclosed
RYNE C. CARNEY Intern Rep. Ed Perlmutter
MICHAEL WARD New —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office

Medical/Disease Research/Clinical Labs MED

-Establishing a Neuroscience Center of Excellence within the FDA -Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R. 5030/S.2706)

LobbyistCovered position, as disclosed
RYNE C. CARNEY Intern. Rep. Ed Perlmutter
MICHAEL WARD —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); White House Office

Bills named: H.R. 5030 (117th), S. 2706 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.